SUPN - Supernus Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.43
+0.25 (+0.92%)
At close: 4:00PM EDT

27.34 -0.09 (-0.33%)
Pre-Market: 8:54AM EDT

Stock chart is not supported by your current browser
Previous Close27.18
Open27.44
Bid0.00 x 900
Ask0.00 x 1100
Day's Range27.19 - 27.70
52 Week Range26.90 - 51.38
Volume458,304
Avg. Volume486,510
Market Cap1.439B
Beta (3Y Monthly)1.27
PE Ratio (TTM)14.14
EPS (TTM)1.94
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents

    Edited Transcript of SUPN earnings conference call or presentation 7-Aug-19 1:00pm GMT

    Q2 2019 Supernus Pharmaceuticals Inc Earnings Call

  • Can Value Investors Pick Supernus Pharmaceuticals (SUPN)?
    Zacks

    Can Value Investors Pick Supernus Pharmaceuticals (SUPN)?

    Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.

  • These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Safely
    Simply Wall St.

    These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Safely

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Supernus Pharmaceuticals Inc (SUPN) Q2 2019 Earnings Call Transcript
    Motley Fool

    Supernus Pharmaceuticals Inc (SUPN) Q2 2019 Earnings Call Transcript

    SUPN earnings call for the period ending June 30, 2019.

  • Supernus Pharmaceuticals (SUPN) Q2 Earnings Top Estimates
    Zacks

    Supernus Pharmaceuticals (SUPN) Q2 Earnings Top Estimates

    Supernus (SUPN) delivered earnings and revenue surprises of 8.93% and -3.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Supernus Announces Second Quarter 2019 Financial Results

    Total revenue of $104.7 million, a 5.2% increase over 2018Net product sales of $102.4 million, a 5.5% increase over 2018Operating earnings of $42.6 million, a 19.3% increase.

  • Do Supernus Pharmaceuticals's (NASDAQ:SUPN) Earnings Warrant Your Attention?
    Simply Wall St.

    Do Supernus Pharmaceuticals's (NASDAQ:SUPN) Earnings Warrant Your Attention?

    It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

  • GlobeNewswire

    Supernus to Host Second Quarter 2019 Earnings Conference Call

    ROCKVILLE, Md., July 23, 2019 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.

  • 4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
    Zacks

    4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal

    In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.

  • Markit

    See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.

    Supernus Pharmaceuticals Inc NASDAQ NMS:SUPNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding SUPN are favorable, with net inflows of $2.29 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • How Do Analysts See Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Performing Over The Next Year?
    Simply Wall St.

    How Do Analysts See Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Performing Over The Next Year?

    In March 2019, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings update. Generally, analysts seem...

  • Here’s What Hedge Funds Think About Supernus Pharmaceuticals Inc (SUPN)
    Insider Monkey

    Here’s What Hedge Funds Think About Supernus Pharmaceuticals Inc (SUPN)

    Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]

  • Thomson Reuters StreetEvents

    Edited Transcript of SUPN earnings conference call or presentation 8-May-19 1:00pm GMT

    Q1 2019 Supernus Pharmaceuticals Inc Earnings Call

  • Read This Before You Buy Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Because Of Its P/E Ratio
    Simply Wall St.

    Read This Before You Buy Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Because Of Its P/E Ratio

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...

  • GlobeNewswire

    Supernus to Present at the Jefferies 2019 Global Healthcare Conference

    ROCKVILLE, Md., May 29, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.

  • 5 Sizzling Small-Cap Stocks to Buy Today
    InvestorPlace

    5 Sizzling Small-Cap Stocks to Buy Today

    Editor's note: This story was previously published in November 2019. It has since been updated and republished.When it comes to investing, smaller is really is better. Small-cap stocks have long beaten their larger rivals in the returns department. That may be hard to realize over the last couple years as investors have flocked to larger multinational firms.But the longer-term picture has small-caps coming out on top by an extra 209%. Moreover, the relationship seems to have once again flipped back to small-caps dominating their big brothers.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd it's easy to see why.For starters, there's plenty of growth to be had in small-cap stocks. An extra $50 million in revenue can really move the needle at a smaller firm. For Apple (NASDAQ:AAPL), it takes a lot more to even register. Secondly, thanks to their domestic focus, small-cap stocks directly benefit more from the rising U.S. economy and the Republican tax plan. Small-cap stocks currently receive around 80% of their revenues from the U.S. and paid an effective tax rate of 31.9%. this compares to 60% domestic revenue and 28% tax rate for larger firms. * 4 Dividend-Focused Utilities Pushing Higher With that and their historical long-term outperformance still in tow, small-cap stocks are where it's at. But what small-cap stocks are worth owning? InvestorPlace has you covered. Here are five of the best.Source: Shutterstock Tableau Software Inc. Class A (DATA)In today's modern era, we create a ton of data. Everything we do, from ordering something online to normal business functions, generates billions of bytes. The trick is seeing how that data translates into usable information. That's where small-cap stock Tableau Software Inc Class A (NASDAQ:DATA) comes in.Tableau produces interactive data-visualization products. This allows organizations to dig deep and instantly see exactly what all that data they generate is doing. Clients include everyone from hospitals to mega-caps like PepsiCo (NYSE:PEP) as it helps managers actually see their business and understand trends. It's a big business, with DATA pulling in more than $290.6 million in revenue during the third-quarter.But those revenues could keep surging higher and higher. That's because Tableau is in the process of shifting its business model. Now that it has gotten companies and organizations hooked, it's moving away from straight pricing to a subscription and SaaS model. That will result in plenty of reoccurring revenues down the road.Already, subscription-based annual recurring revenue jumped 160% year over year. More importantly, DATA recent guidance reaffirmed the idea that large increases are set to be the standard for the time being.With more and more and more data being created each second, Tableau's future is pretty secured. That make it one of the best small-cap stocks to buy today.Source: Shutterstock Supernus Pharmaceuticals (SUPN)Most small-cap biotech stocks are the stereotypical lotto tickets. They feature no marketed drugs, no revenues and mega-sized losses. That makes small-cap Supernus Pharmaceuticals (NASDAQ:SUPN) a rarity worth owning.SUPN focuses on diseases affecting the central nervous system and has not one, but two drugs on the market. That's a remarkable feat unto itself. But what's really impressive is that sales of both Trokendi XR and Oxtellar XR have been swift. Analysts expect the drugs used to treat epilepsy, migraines and seizures to pull in more than $385 million this year. That makes SUPN a profitable biotech as well -- with EPS jumping 79% in its latest reported quarter. * 10 Retirement Stocks That Won't Wilt in a Bear Market As if that wasn't enough, Supernus has a rich pipeline of new therapies in various stages of trials. This includes using Oxtellar XR for other versions of epilepsy and as a treatment bipolar disorder. New compounds for impulse aggression, depression and ADHD have the potential to be multibillion-dollar opportunities. Given SUPN's conservative management and history of scoring drugs, the potential for continued revenue growth is great.With plenty of cash in the bank and coming in from drug sales, SUPN certainly breaks the small-cap biotech stock mold.Source: Shutterstock ON Semiconductor Corp. (ON)Small-cap stocks in the tech sector can be wonderful places to find growth especially if you get in early on their growth stories. That could be the case with ON Semiconductor Corp. (NASDAQ:ON).ON isn't a new name. The small-cap was a maker of strictly low-margined, high-comedized memory chips. But its newfound focus certainly makes it a "new" stock.The problem is that memory chips aren't exactly a booming business. In fact, they are so commoditized end-users actually trade futures contracts on them. To counteract this, ON made a series of smart acquisitions and moves to switch focus to higher margined specialty chips. Now, ON is now a player in the automotive, power management and image sensors sectors.The moves seem to be working. Revenues at ON increased more than 11% in Q4 2018 and tacked on another 8% for Q1 2019 while diluted EPS surged 52% year-over-year. Clearly, management made the right decision.At the decision for investors to buy is an easy one. Thanks to the recent tech rout, shares of ON are trading for peanuts. Right now, the small-cap stock can be had for a P/E of under 8. That's insanely cheap considering its growth projections and higher guidance.Source: Shutterstock Watts Water Technologies Inc (WTS)Many investors have this idea that small-cap stocks don't generate dividends because they need to plow every extra cent back into their businesses to grow and stay afloat. This simply isn't true. Small-cap stocks can be wonderful dividend stocks. Just ask Watts Water Technologies Inc (NYSE:WTS). Watt's has been paying a dividend since 2001 and has managed to grow its payout by over 83% in that time.WTS offers a variety of water-focused infrastructure products. This includes everything from pipes and valves to more advanced fare like smart-meters and water-conservation products. This puts right in the crosshairs of two mega-trends. Water scarcity and delivery are becoming a hotbed issues for the planet as well as the United States. * 7 Dangerous Dividend Stocks to Stay Far Away From Upgrading this vast infrastructure is vital. At the same time, infrastructure seems to be the one thing the Democrats and President Trump agree on. The chance for a "pick and shovel" plan and higher government spending on replacing old water infrastructure seems very good.With that, WTS is poised to get a bunch of revenues and drive profits further. Because Watts business model includes a hefty focus on repair/replace, the firm has historically generated free cash flows that exceed 100% of their income. With WTS already reporting record profits last quarter, any increased spending will only translate into more gains/profits.Watts isn't the most exciting equity to watch, but it is a prime example of how small-cap stocks can pay big growing dividends.Source: Karen Neoh via Flickr Barnes Group Inc. (B)There are plenty of small-cap stocks that aren't household names, but provide plenty of muscle for bigger firms. A perfect example would be Barnes Group Inc. (NYSE:B). B counts Ford (NYSE:F), United Technologies (NYSE:UTX), and Boeing (NYSE:BA) as its customers.Barnes operates in two sectors: aerospace and industrial components. The industrial side of things makes everything from springs to plastic injected molded products. Revenues from this segment tend to be stable and provide a nice base of profits for B. But what really is exciting is its aerospace business.Here, Barnes does a lot of heavy lifting in terms of components and pieces for turbines, airframes and other vital systems for planes. This includes a hefty dose of military-specific hardware. As a result, margins for this segment remain mega-sized at over 20% and generate the fast bulk of its profits. With military spending on the rise and its core aerospace customers seeing more business, Barnes confines to see a steady increase in its bottom line.Barnes stock isn't super cheap right now, but it does reflect the great aerospace/military spending environment. And investors do get a 1.11% dividend yield -- a pretty decent yield for small-cap stocks.As of this writing, Aaron Levitt is long SUPN More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Turnaround Stocks to Watch * 7 Aerospace Stocks to Buy That Were Previously Grounded * 5 Pharma Stocks to Stay Away From Compare Brokers The post 5 Sizzling Small-Cap Stocks to Buy Today appeared first on InvestorPlace.

  • 3 Top Value Stocks to Buy in May
    Motley Fool

    3 Top Value Stocks to Buy in May

    Deep-value stocks like Supernus Pharmaceuticals and Party City look attractive now.

  • EA, Supernus Pharmaceuticals, and More: Stocks on the Move After Hours
    Insider Monkey

    EA, Supernus Pharmaceuticals, and More: Stocks on the Move After Hours

    It's been a busy Tuesday as usual and a lot of stocks such as Electronic Arts Inc. (NASDAQ:EA), Kinross Gold Corporation (NYSE:KGC), Inogen Inc (NASDAQ:INGN), Supernus Pharmaceuticals Inc (NASDAQ:SUPN), and 3D Systems Corporation (NYSE:DDD) are on the move in extended market trading after market close. Let's analyze why each stock is on the move and how the smart money, hedge funds […]

  • Supernus Pharmaceuticals (SUPN) Lags Q1 Earnings and Revenue Estimates
    Zacks

    Supernus Pharmaceuticals (SUPN) Lags Q1 Earnings and Revenue Estimates

    Supernus (SUPN) delivered earnings and revenue surprises of -22.73% and -18.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?